Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study

BMC Medicine, Год журнала: 2024, Номер 22(1)

Опубликована: Март 13, 2024

Abstract Background Paxlovid has been shown to be effective in reducing mortality and hospitalization rates patients with coronavirus disease 2019 (COVID-19). It is not known whether can reduce the risk of cardiovascular diseases (CVD) COVID-19-surviving autoimmune rheumatic (AIRDs). Methods TriNetX data from US Collaborative Network were used this study. A total 5,671,395 AIRDs enrolled between January 1, 2010, December 31, 2021. People diagnosed COVID-19 included cohort ( n = 238,142) 2022, 2022. The Study population was divided into two groups based on use. Propensity score matching generate matched baseline characteristics. hazard ratios (HRs) 95% confidence intervals outcomes, admission rate, intensive care unit (ICU) rate calculated non-Paxlovid groups. Subgroup analyses sex, age, race, group, sensitivity for use within first day or 2–5 days diagnosis performed. Results associated lower risks cerebrovascular complications (HR 0.65 [0.47–0.88]), arrhythmia outcomes 0.81 [0.68–0.94]), ischemic heart disease, other cardiac disorders 0.51 [0.35–0.74]) naming failure 0.41 [0.26–0.63]) deep vein thrombosis 0.46 [0.24–0.87]) belonging thrombotic AIRD COVID-19. Compared Non-Paxlovid major adverse events 0.56 [0.44–0.70]) any outcome mentioned above 0.76 [0.66–0.86]) group. Moreover, 0.21 [0.11–0.40]), 0.68 [0.60–0.76]), ICU 0.52 [0.33–0.80]) significantly group than appears more male, older, Black AIRD. severe conditions reduced prescribed diagnosis. Conclusions a CVDs

Язык: Английский

---

A Tale of Two Drugs: Molnupiravir and Paxlovid

Mutation Research/Reviews in Mutation Research, Год журнала: 2025, Номер 795, С. 108533 - 108533

Опубликована: Янв. 1, 2025

Язык: Английский

---

Synergistic interference with SARS-CoV-2 replication by molnupiravir-derived N4-hydroxycytidine and inhibitors of CTP synthetase in cell culture

Virology, Год журнала: 2025, Номер unknown, С. 110598 - 110598

Опубликована: Июнь 1, 2025

Язык: Английский

---

Antiviral and antiretroviral prodrugs

Elsevier eBooks, Год журнала: 2024, Номер unknown, С. 219 - 232

Опубликована: Окт. 4, 2024

---